This paper reviews the evidence on combining antidepressants (ADs) for treatment of major depressive disorder. Although widely used and usually safe, the efficacy of even the most widely prescribed combinations of ADs has not been established by properly controlled, adequately powered, clinical trials. This stands in contrast to several adjunctive strategies for AD nonresponders, including adjunctive lithium, thyroid hormone, or newer-generation antipsychotics. The wide use of AD combinations no doubt reflects the limited efficacy of commonly used ADs and the unmet need for effective strategies for patients with treatmentresistant depression. Although of unproven efficacy, potential merits of combining selected ADs include: 1) avoiding discontinuation-emergent symptoms and cross-titration schedules, 2) at worst, the second AD should be as effective in combination as it would be as a monotherapy following a switch, and 3) the possibility of complementary neuropharmacologic effects that may enhance efficacy or improve tolerability. The dearth of controlled studies of such a commonly used strategy for such a highly prevalent condition is symptomatic of shortcomings in the way clinically relevant research is funded, points to the need for industry-academic-federal collaborations, and underscores the need for large, practicebased, research groups that can efficiently complete publicly funded studies of high public health impact.
T his paper reviews the evidence on combining ADs to treat major depressive disorder and concludes that this widespread practice is not justified by the current level of empirical support. Indeed, in an era in which our clinical practices should be explicitly guided by the principles of EBM whenever possible, it is not too much of an overstatement to suggest that the evidence base in support of combining ADs is so thin that the enthusiasm for combining ADs is better described as a fad than the practice of EBM. From the outset of this review, it is acknowledged that it is usually not dangerous to combine many of the newer ADs and that credible neuropharmacologic rationales can be articulated to defend using several of the more commonly used AD combinations. Nevertheless, it is a simple fact that there have not been enough well-controlled studies of even the most widely used combinations of ADs to provide an adequate empirical basis to support such widespread use.
Before considering the state of the evidence of currently used combination strategies, it may be worthwhile to briefly review the history of combining ADs. In fact, this is not a new strategy and the potential therapeutic merits of combining different types of ADs was recognized not too many years after the MAOIs and TCAs were first introduced. Thenas is still true today-clinicians sometimes combined ADs because they had patients who did not obtain adequate benefit from their favourite medications alone. Even in those early years of psychopharmacology there was a theoretical rationale for trying to combine ADs, as it was fairly certain that the TCAs and MAOIs initiated their therapeutic effects through different mechanisms of actions and, as such, these medications may show additive or complementary effects. However, there were real risks with combining TCAs and MAOIs, including 2 that were potentially lethal (hypertensive crises and 5-HT syndrome). For these reasons, TCA plus MAOI combinations were considered to be relatively contraindicated and generally were only used by expert psychopharmacologists for treatment of patients with the most advanced cases of TRD. Clinical experience indicated that some combinations should be avoided (for example, clomipramine and tranylcypromine) and that there were fewer problems with combined therapy when the TCA (often amitriptyline) was started first and titrated to a lowend therapeutic dosage (for example, 100 to 150 mg daily), with the MAOI (often phenelzine) subsequently slowly titrated to a low-end therapeutic dosage (for example, 30 to 45 mg daily). However, as reviewed 15 years ago, 1,2 only a small number of RCTs of this strategy were conducted. These studies did not establish the superior efficacy of combined therapy in TRD and, in fact, the results of a small (n = 17) study by Davidson et al 3 suggested the TCA plus MAOI combination was significantly less effective than ECT. These studies did provide some reassurance that carefully orchestrated combinations of TCAs and MAOIs could be prescribed with reasonable safety. Nevertheless, by the end of the first generation of psychopharmacology, few clinicians felt comfortable combining TCAs and MAOIs, and the practice continued to be classified as a type of polypharmacy, which in turn was considered to be a potential indicator of bad practice.
The introduction of SSRIs changed the therapeutic landscape of depression in many ways and, for the most part, these changes have been beneficial to our patients. Indeed, the SSRIs became so widely accepted, so quickly, that-by the mid-1990s-they had largely supplanted the TCAs as the treatment of first choice for depressed outpatients. The popularity of the SSRIs directly led to a new unmet need: identification of effective strategies for SSRI nonresponders. The perceived magnitude of this need may have been a direct result of the high selectivity of the SSRIs; that is, the well-known advantages in tolerability and safety of SSRIs, compared with the TCAs, were arguably at the expense of reduced efficacy, especially for patients with severe depression. Although this position is still somewhat controversial even 20 years later, it was initially supported by the results of several early inpatient RCTs that compared clomipramine with the SSRIs citalopram 4 and paroxetine, 5 and subsequently reinforced by results of a meta-analysis of 25 inpatient RCTs. 6 Regarding the relevance of selectivity, it is noteworthy that Anderson 6 found no appreciable difference in efficacy in the studies that contrasted the SSRIs with the more noradrenergically selective, secondary amine TCAs (that is, desipramine and nortriptyline) and their tetracyclic cousin maprotiline. It was thus posited that the apparently greater efficacy of tertiary amine TCAs, such as amitriptyline and clomipramine, was attributable to the breadth of their actions, including direct effects on serotonergic and noradrenergic neurotransmission. One immediate therapeutic implication of this hypothesis was the possibility that the effectiveness of SSRIs could be enhanced by adding one, the noradrenergically active TCAs.
As clinical experience with SSRI plus TCA combinations accumulated, it was readily apparent that the SSRIs were much safer to use in tandem with TCAs than were the MAOIs, and, aside from some concerns pertaining to drug-drug interactions, these combinations were generally well tolerated. Such positive clinical experiences opened a Pandora's box, and the strategy of combining ADs rapidly expanded to include combinations with other newergeneration ADs, such as bupropion, mirtazapine, and the SNRI venlafaxine.
As we near the end of the second generation of AD pharmacotherapy, it is fair to say that the safety of the newer ADs has permitted a lot of clinical experimentation with various combinations of drugs, and such experience, coupled with the persisting clinical imperative to find effective remedies for patients who do not respond to preferred first-and second-line ADs, has fostered a sea change in the attitudes of psychiatrists and a loosening of standards of those who perform quality assurance reviews; a practice that was once frowned on is now de rigueur, and what was formerly labelled polypharmacy is now described by terms such as rational co-therapy. However, relative safety and less pejorative labels are not the same thing as empirical validation and, as reviewed below, the evidence base for combined AD therapy is still remarkably thin.
The Current State of the Evidence
Generally a minimum of at least 2 positive, well-controlled RCTs are required before a strategy is considered to have established efficacy. Regarding combining ADs, this rule probably should apply to each of the major combinations (for exampe, SSRIs plus TCAs and SSRIs plus bupropion). Lam et al 7 completed a comprehensive review of case series and studies conducted prior to July 2001 and found no instance in which there were 2 positive RCTs. They concluded that there was limited evidence that AD combinations were effective for TRD and recommended that additional, largerscale studies be conducted. Since that time, a handful of 
TCA Plus SSRI Combinations
Lam et al 7 identified numerous case series, but only a single RCT of a TCA plus SSRI combination. 8 Among the case series that they reviewed, without a doubt the most influential was that of Nelson et al, 9 which used a carefully standardized inpatient protocol to evaluate combined fluoxetine and desipramine therapy. Their study 9 is noteworthy both for serial measurement of plasma drug levels and for inclusion of a reasonably well-matched historical control group treated with desipramine alone. In their protocol, inpatients were treated for 4 weeks with desipramine (median dosage: 125 mg daily), with dosage adjusted to achieve adequate blood levels and, from day 2 to day 14 of the protocol, fluoxetine at 20 mg daily. Among the 14 inpatients who completed 4 weeks of therapy, 10 (71%) remitted, compared with only 6 of 42 (14%) patients in the historical comparison group who were treated with desipramine alone (median dosage: 175 mg daily).
This truly exemplary pilot study 9 provided a strong justification for further research on SSRI plus TCA combinations; though, in the enthusiasm for its findings, its methodologic limitations were often overlooked. Specifically, it was an open-label study, not an RCT, and treatment was administered and evaluated by clinicians who were likely to have believed that the combination had superior therapeutic properties. Moreover, although the apparent advantage of the combination over desipramine alone is striking, the historical nature of the control group, and because patients were not randomly allocated to therapy groups, leaves open the possibility of a cohort effect (that is, the newer patient group was easier to treat than the historical comparison group). This is particularly important because, without a contemporaneous comparison group treated with fluoxetine alone, it impossible to rule out the possibility that the investigators had unknowingly recruited a population that was particularly responsive to the SSRI, which was still a novel class of medication at the time. It was also true that, despite the investigators' concerted efforts to take into account the pharmacokinetic interaction of fluoxetine and desipramine, patients treated with combined therapy had higher plasma levels of desipramine than did those in the historical control group. Thus, even if the combination actually was more efficacious-a conclusion that cannot be reached because of the nature of the study-the advantage may have been attributable to the higher blood level of the TCA.
Results of the small RCT of Fava et al 8 suggested that lower doses of desipramine were not efficacious in combination with fluoxetine. In that trial, 41 depressed outpatients who had not responded to 8 weeks of treatment with fluoxetine (20 mg daily), were randomized to 4 weeks of double-blind treatment, with fluoxetine at increased dosage (40 to 60 mg daily), compared with fluoxetine plus desipramine (25 to 50 mg daily) or fluoxetine plus lithium (300 to 600 mg daily). They found no significant differences in outcome, though numeric trends favoured the group that received higher doses of fluoxetine (for example, a remission rate of 53%, compared with remission rates of 29% and 25% for the groups that had lithium and desipramine added to fluoxetine). Given the low remission rates observed in the latter 2 groups, it would have been worthwhile to have included a fourth arm, in which patients received ongoing therapy with 20 mg of fluoxetine and 2 placebo tablets.
These investigators subsequently conducted a second, larger study 10 using the same protocol. The results of the second study, which randomized 101 fluoxetine nonresponders, largely mirrored those of the first trial, with response rates of 42%, 29%, and 24% for the higher dose fluoxetine and desipramine and lithium augmentation groups, respectively. When considered together, the findings of these studies indicate that low doses of a TCA do not enhance an SSRI. Thus, if a TCA is to be added to an ineffective SSRI, the dose of that medication should be titrated high enough to ensure that plasma levels are within the therapeutic range.
A third study by Nelson et al, 11 which was not limited to patients with TRD, evaluated the combination of fluoxetine and higher doses of desipramine. In this trial, 39 inpatients were randomly assigned to 6 weeks of double-blind treatment with fluoxetine or desipramine, singly or in combination. The fluoxetine dosage was fixed at 20 mg daily; and desipramine dosages were adjusted by an unblinded monitor to ensure adequate plasma levels. Average dosages of desipramine were 98 mg daily in the combined therapy group and 294 mg daily in the monotherapy group. In contrast to the findings of Fava et al, 8, 10 there was evidence of an additive effect with a significant difference in remission rates favouring the group on combined therapy (54%), compared with the groups that received fluoxetine (7%) or desipramine (0%) monotherapy. Thus, for hospitalized patients with relatively severe depression and a low likelihood of responding to either fluoxetine or desipramine as monotherapies, the combination of therapeutic doses of desipramine and fluoxetine had superior efficacy and resulted in the use of much lower doses of the TCA to achieve therapeutic blood levels.
The findings of Nelson et al 11 are entirely consistent with the conclusions of the aforementioned meta-analysis of Anderson, 6 namely, that for depressed inpatients, AD strategies that target both norepinephrine and 5-HT are superior to more highly selective ADs. It remains to be seen if these findings would hold true in a study of outpatients with TRD or if the combination of an SSRI and either desipramine or nortriptyline would be superior to treatment with higher doses of so-called dual reuptake inhibitors, whether older (for example, clomipramine or amitripyline) or newer (for example, venlafaxine or duloxetine). No such studies have been completed.
Perspective

SSRIs Plus Bupropion
In the United States, bupropion had largely replaced the TCAs as the drug of choice for combining with SSRIs by the mid-1990s. When compared with TCAs, important perceived advantages of this combination included:
1. bupropion has a more favourable side effect and tolerability profile than TCAs, 2. the possibility of targeting both norepinephrine and dopamine (whereas desipramine affects only norepinephrine reuptake, bupropion is classified as a norepinephrine dopamine reuptake inhibitor), 3. the widely held clinical belief that bupropion may help to counteract SSRI-mediated sexual side effects, and 4. bupropion is not a substrate for cytochrome P450 isozyme CYP2D6 and, as such, blood levels are not increased by prescription in combination with fluoxetine or paroxetine.
Lam et al 7 reviewed the several early case series describing this strategy, which suggested this combination was both well tolerated and likely an effective strategy. However, there were no rigorous double-blind RCTs of this combination at the time of their review.
The state of the evidence has not changed much during the past 9 years. Two open-label active comparator controlled studies have been published, 12, 13 and, when considered together, these trials provide only limited support for the strong clinical enthusiasm for this combination.
Lam et al
12 studied 61 patients who had a history of nonresponse to an adequate trial of at least 1 AD and nonresponse to a prospective trial with the treating clinician's choice of either citalopram or bupropion sustained release (doses not reported). Using a quasi-randomized design (that is, treatment assignments were alternated every other month), nonresponders were treated with either the alternate medication (n = 29) or the combination of bupropion and citalopram (n = 32). Tolerability indices were comparable in the 2 groups and response rates were 56% for the group that received combined treatment and 38% for the group that received a switch in medication. Although these proportions did not differ significantly, an effect of this magnitude-if replicable in a larger study-would be clinically meaningful. The group receiving combined treatment did obtain a significantly greater reduction in depressive symptoms and a significantly higher remission rate (28%, compared with 7%) than the group treated with citalopram or bupropion alone.
A larger study of the SSRI plus bupropion combination was conducted as part of the STAR*D trial. 13 This large multicentre study used an open-label design and an equipoise-stratified randomization strategy to compare 7 different options (4 switching and 3 adjunctive) for depressed outpatients who were first treated for up to 14 weeks with citalopram at dosages of up to 60 mg daily. Among the more than 2700 patients who received an adequate course of citalopram therapy, about 1200 did not remit and participated in a second treatment trial. Unfortunately, an unanticipated consequence of the randomization strategy was that few patients were at equipoise about the decision to switch, compared with to augment, and it was not possible to conduct the planned comparison of the group randomly assigned to receive the citalopram plus bupropion strategy, compared with the groups that received the most relevant switch strategies (sertraline, bupropion, or venlafaxine). Visual inspection of the results suggests that the citalopram plus bupropion combination was more effective than switching to bupropion monotherapy, with about a 10% difference in HDRS remission rates. 13, 14 However, there were important differences in the patients who opted for switching, compared with those who opted for adjunctive therapies, which make hazardous such post hoc comparisons of the nonrandomized groups. Of greatest relevance, patients who opted for the randomized switching strategies had higher levels of depressive symptoms and had more side effects with citalopram therapy than had those who opted to remain on citalopram and be randomized to various augmentation strategies. Thus the only relevant contrast possible was the one comparing citalopram plus bupropion with the combination of citalopram and buspirone, a nonbenzodiazepine anxiolytic that is classified as a 5-HT 1A partial agonist. As a placebo-controlled trial of buspirone augmentation completed before the STAR*D trial had failed to document adjunctive AD efficacy, 15 this strategy was viewed by some of the investigators as analogous to an active placebo. A total of 565 patients were randomized to these 2 arms. Although drug treatment was provided open label, the primary dependent variable, the HDRS, was administered by an independent evaluator without knowledge of treatment assignment. There were no differences in response or remission rates at the end of up to 12 weeks of treatment; both groups had HDRS remission rates of 30%. There was a small, but statistically significant advantage for the citalopram plus bupropion group on the self-report symptom measure. Significantly more patients also dropped out of treatment with citalopram plus buspirone, owing to intolerable side effects (21%, compared with 13% in the group receiving adjunctive bupropion). Despite these modest advantages, the results of the STAR*D trial did not provide a ringing endorsement for the use of the SSRI plus bupropion combination.
SSRIs and (or) SNRIs Plus Mirtazapine and (or) Mianserin
Mirtazapine and mianserin, a closely related drug not available in the United States or Canada, are mechanistically distinct ADs that have no appreciable effect on monoamine uptake transporters. However, these drugs do modulate norepinephrine and 5-HT neurotransmission via complex mechanisms that include antagonism of alpha-2 autoreceptors and heteroreceptors, as well as blockade of 5-HT 2 , 5-HT 3 , and histamine receptors. The potential advantages of combining these ADs with SSRIs and SNRIs are several, including broadening symptomatic coverage for insomnia and diminished appetite-symptoms that are not reliably improved by SSRIs and SNRIs-and counteracting common gastrointestinal side effects such as nausea.
Lam et al 7 identified 2 RCTs of mianserin augmentation of ADs and several case series of mirtazapine augmentation. Both studies of mianserin augmentation of SSRI nonresponders yielded some evidence in favour of the combination, compared with fluoxetine alone.
Four randomized studies of mirtazapine in combination with other ADs have been subsequently published. In the first RCT of an SSRI plus mirtazapine combination, 26 outpatients with a history on nonresponse to an adequate trial of AD monotherapy were randomized to receive 4 weeks of adjunctive mirtazapine (15 to 30 mg daily) or placebo. Adjunctive mirtazapine was found to be effective, with statistically significant reduction in depressive symptoms and a final remission rate of 45%, compared with 13% for the patients who received placebo in addition to ongoing AD treatment.
The second randomized study evaluated the combination of mirtazapine and venlafaxine as the fourth step in the multistage STAR*D trial. As with the other STAR*D comparisons, this trial involved open-label administration of study medications and independent assessments by clinical evaluators who were not aware of the treatment assignment. A total of 109 patients who had not responded to 3 sequential treatment trials were randomly assigned to treatment with either the AD combination (mirtazapine, mean dosage 36 mg daily; venlafaxine extended release, mean dosage 210 mg daily) or the MAOI tranylcypromine (mean dosage, 37 mg daily). Some portion of the study group had not responded to mirtazapine and (or) venlafaxine monotherapy during earlier stages of the study. Neither treatment strategy was particularly effective, with final remission rates of 7% and 14% for the tranylcypromine and combination therapy groups, respectively. Nevertheless, the combination strategy was associated with significantly greater reduction of depressive symptoms and significantly lower attrition, owing to side effects. These findings suggest that the combination of venlafaxine and mirtazapine has certain advantages, compared with tranylcypromine for patients with more advanced grades of TRD who have not benefited adequately from several prior treatments. This conclusion is limited by the relatively low average dose of tranylcypromine, which indicates that less than one-half of the patients who received this therapy actually took an adequate dose of medication. An additional conclusion suggested by this latter finding is that clinicians in contemporary practice are better able to implement a trial of combination therapy with newer-generation ADs than they are able to implement an adequate trial with an MAOI.
The 2 most recent studies of mirtazapine combination therapy were not studies of TRD, but rather tested the hypothesis that ADs could be combined from the initiation of therapy to hasten response and (or) improve AD outcomes. The first trial randomized 61 outpatients to 6 weeks of double-blind therapy with mirtazapine (30 to 60 mg daily) or paroxetine (20 to 40 mg daily), either singly or in combination. The authors reported that the mirtazapine plus paroxetine combination was well-tolerated and attrition was no greater on the combination than on the 2 monotherapies. There was a significantly greater decrease in MADRS scores in the combination group, compared with the monotherapy groups after 4, 5, and 6 weeks of double-blind therapy, with final MADRS remission rates of 43% for combined treatment, compared with 19% and 26% for the mirtazapine and paroxetine monotherapy groups, respectively. Although these differences were not statistically significant in this small study, they would be considered clinically meaningful if replicable in larger samples.
The most recent study, which enrolled 105 depressed outpatients initiating AD therapy, randomly assigned patients to receive 6 weeks of therapy with fluoxetine alone (20 mg daily, plus a placebo) or in combination with mirtazapine (30 mg daily); 2 other groups received mirtazapine in combination with venlafaxine (225 mg daily, titrated in 14 days) or bupropion (150 mg daily). Compared with fluoxetine monotherapy, all 3 groups receiving AD combinations had significantly greater improvements in depressive symptoms and numerically greater remission rates (25% for fluoxetine, 52% for fluoxetine plus mirtazapine, 58% for mirtazapine plus venlafaxine, and 46% for mirtazapine plus bupropion). The 3 combined treatment strategies were reasonably well tolerated and, when the combination was compared with fluoxetine monotherapy, the addition of mirtazapine was not associated with a significant increase in side effect burden or attrition. Although the results strongly suggest that combining ADs resulted in better short-term outcomes, the absence of a mirtazapine monotherapy arm is a critical shortcoming regarding the interpretability of these findings.
Summary
The paucity of RCTs on combined AD strategies, coupled with inconsistencies in the findings of the studies that have been completed, justify the conclusion that this commonly used approach has not been adequately researched. That most of the studies suggest that combining ADs of dissimilar structure and mechanism of action may convey some greater benefit (compared with monotherapies), coupled with the need for more effective treatments for our depressed outpatients, certainly provides a strong justification for further research on this topic.
So What Is The Problem With So Much Combined Therapy, Really?
Having disclosed early on that I use AD combinations in my clinical practice and having spent some time reviewing both the rationales and potential advantages of combining ADs, one might actually begin to wonder if I have accidentally written a perspective paper advocating the use of AD combinations. So, I will cut to the chase: although there is some evidence that some AD combinations are probably effective and there is ample clinical evidence that many of the newer ADs can be safely combined, there remains one fundamental problem, namely, there is a dearth of evidence on the efficacy-both absolute (compared with placebo) and relative (compared with other standard strategies)-of combined AD treatment. This problem is amplified by 3 almost axiomatic observations:
1. Depression is a very common condition. 2. AD drugs are among the most widely prescribed medications. 3. Nonresponse to first-line ADs is a common occurrence.
For example, fully 50% of the depressed outpatients who began AD therapy in the STAR*D trial did not experience an adequate response to up to 12 weeks of therapy with citalopram at dosages of up to 60 mg daily. 13 As the STAR*D patient population was selected to be generalizable to clinical practice, and if one accepts the epidemiologic data that about 10% of the adults in the United States and Canada will be prescribed ADs during the next year, then we can expect that about one-half that number will need their doctor's help with finding an alternate treatment. Thus, each month, several hundred thousand citizens of the United States and Canada will expect their doctor to know what to do next if he or she recommends a combination of 2 ADs. Although I neither worship exclusively at the EBM temple nor expect that there will be multiple adequately powered, properly controlled clinical trials to help guide all of the decisions that we make in clinical practice, I do think that it is noteworthy that we must deviate from the path of EBM so early in the treatment algorithm for so many patients.
Given a problem of such immense public health significance, we should strive to have Grade A-level evidence available to guide our treatment strategies whenever possible. Although it is true that the potential merits of certain treatment strategies are often observed in nonresearch settings and first described in letters to the editor, case reports, and case series, it is also essential that such promising observations be subjected to rigorous and well-controlled studies. For an AD treatment, the operational definition of a well-controlled study consists of random assignment, double-blind administration of study medications, use of a standardized protocol so that the experiment is replicable, and use of reliable scales to assess the key dependent variable in a manner that is free of potential bias. The study should also be large enough to have a decent chance of rejecting the null hypothesis (that is, the addition of AD x to AD y will result in significantly higher response rate than to simply continue AD y (along with a double-blind placebo) or to switch to AD z. Until we can implement and sustain a clinical research infrastructure that permits such studies to be completed routinely, we will continue to fall short of our goal to provide proven treatment strategies for our patients.
